Formulation containing anti-inflammatory androstane derivative
AssigneeSmithKline Beecham Corporation
InventorsKeith Biggadike, Amyn Pyarali Sayani, Ian Richard Buxton, Kenton Lewis Reed
Life of this patent
Estimating the term…
Abstract
There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) 1 or a solvate thereof.
Claims25
1 A pharmaceutical formulation which comprises:
- an aqueous suspension of particulate compound of formula (I)
- 8
- or a solvate thereof:
A pharmaceutical formulation according to claim 1 which comprises:
- one or more suspending agents.
A pharmaceutical formulation according to claim 1 which comprises:
- one or more preservatives.
A pharmaceutical formulation according to any claim 1 which comprises:
- one or more wetting agents.
A pharmaceutical formulation according to claim 11 wherein the polyoxyethylene (20) sorbitan monooleate is present within the formulation in an amount of between 0.001 and 0.05% (w/w), based on the total weight of the formulation.
A pharmaceutical formulation according to claim 1 which comprises:
- one or more isotonicity adjusting agents.
A pharmaceutical formulation according to claim 1 characterised in that it is isotonic with fluids of the nasal cavity.
A pharmaceutical formulation to claim 1 which is buffered to a pH of between 5 and 7.
A pharmaceutical formulation according to claim 1 wherein the compound of formula (I) or solvate thereof is present within the formulation in an amount between 0.005% and 1% (w/w), based on the total weight of the formulation.
A pharmaceutical formulation according to claim 1 wherein the compound of formula (I) is used as unsolvated polymorph Form 1.
A pharmaceutical formulation according to claim 1 which comprises
- (i) one or more suspending agents;
- (ii) one or more preservatives;
- (iii) one or more wetting agents;
- and
- (iv) one or more isotonicity adjusting agents
A container comprising a pharmaceutical formulation according to claim 1 suitable for delivering it in the form of a nasal spray.
A method of treatment of allergic rhinitis which comprises administering to a patient a pharmaceutically acceptable amount of a formulation according to claim 1.
Dependencies are inferred from the claim text.